(OTCBB:CEXI) CDEX Inc

Turning Pennies into dollars: (OTCBB:CEXI) CDEX Inc

Are you a public company looking for exposure?

Contact RealPennies.com - 212-662-2147



For more info: http://www.realpennies.com/otc/cexi

CDEX Files FY2008 10KSB; Continued Record Revenues

(OTCBB:CEXI) CDEX Inc.

CDEX Files FY2008 10KSB; Continued Record Revenues

Tuesday February 17, 9:15 am ET

TUCSON, AZ-Feb 17, 2009 - CDEX Inc. filed its FY08 10KSB on February 13; FY08 accomplishments included record revenues (65% above FY07), 74% gross margins , international expansion of the ValiMed product line, more than doubling of the ValiMed hospital client base, introduction of a new product line ), and domestic and international sales of both ValiMed and the ID2 Meth Scanner.

"FY08 was a year of positioning and great accomplishments for CDEX," said Malcolm Philips, CDEX CEO. "Even while we expanded significantly our existing ValiMed product line, introduced the new ID2 product line, and positioned ourselves for the future by increased R&D spending, we still reduced our net operating loss by over 18%. While the global economic downturn presents major challenges for every company, including CDEX, we are moving in the right direction and fully expect to be cash flow positive by the last quarter of 2009 - our next major goal." (See expanded comments regarding FY08 in the Management Briefing Section of the CDEX Web Site at www.cdexinc.com.)

About CDEX

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 product line detects trace amounts or illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must raise additional funds as stated periodically in its SEC filings. For more information, visit www.cdexinc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Contact:

Contact: Malcolm Philips Email Contact   Source: CDEX Inc.

Profile for CDEX Inc.

CDEX, Inc., a technology development company, engages in the development and marketing of chemical detection technologies to develop products in the healthcare, security, and brand protection markets in the United States and internationally. The company offers ValiMed product line comprising ValiMedImpaired Clinician Solution that and ValiMed Patient Safety Solution, which are used for the validation of prescription and compounded medications to provide for patient safety, training of medical staff regarding compounding practices, and detection of the diversion of narcotics and controlled substances. It also provides CDEX ID2 Product Line containing both handheld and table top devices that d... Detailed CEXI Company Description...

LAST $0.10 USD

Find out more about CEXI



Realpennies.com



Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on http://www.realpennies.com/start.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.

RealPennies.com

Phone: 212-662-2147

info [at] realpennies.com